Prabhudas Lilladher has maintained a 'Buy' rating on KIMS Hospitals with a price target of Rs 850. While the company is seeing strong revenue growth, profit has dipped due to aggressive expansion costs. Investors are currently tracking the company’s Rs 2,100 crore fundraising plan and the breakeven timeline for its new hospitals.
Prabhudas Lilladher has retained its 'Buy' outlook on Krishna Institute of Medical Sciences (KIMS) Hospitals, setting a target price of Rs 850 per share. The brokerage’s stance comes amidst a phase where the hospital chain is heavily investing in new capacity, which has driven strong top-line growth but created temporary pressure on bottom-line profits.
In the first quarter of FY27, KIMS reported a significant 36.1% year-on-year rise in revenue, reaching Rs 1,196 crore. However, net profit declined by 56% to Rs 37 crore during the same period. This mismatch between revenue and profit is largely attributed to higher depreciation and interest expenses, which are standard for capital-intensive, new-build hospital projects during their initial ramp-up phase.
Fundraising and Expansion Strategy
To fund its ongoing growth and manage its balance sheet, the board of KIMS approved a capital raising plan of Rs 2,100 crore on August 3, 2026. This includes Rs 1,500 crore to be raised through a Qualified Institutional Placement (QIP) at Rs 755 per share, and an additional Rs 600 crore via warrants issued to promoters at Rs 779 per share. This move is designed to provide the necessary liquidity to continue the company's aggressive greenfield expansion strategy across key markets.
Management has been focused on improving operational efficiency in newer clusters, particularly in Karnataka and Kerala. The company recently overhauled its leadership team in these regions to speed up the stabilization of new facilities. The brokerage highlighted that the reduction in losses at the Bengaluru (Electronic City) unit is a positive sign of the company's execution capabilities. Management expects these newer greenfield units to reach a break-even point within the next one to two quarters.
Risk and Outlook
While the expansion strategy aims for long-term growth, it carries inherent risks. The company is currently experiencing margin compression, a natural consequence of the heavy upfront spending required to launch and stabilize new hospitals. Investors should watch the execution of these projects closely; the success of this strategy depends on the company's ability to drive patient volume and reach profitability in these new markets quickly.
Additionally, as the company uses leverage to fund its expansion, monitoring finance costs and debt levels will remain important. The primary monitorable for investors in the coming quarters will be the speed at which these new hospitals turn profitable, which should eventually help in easing the pressure on overall margins and free up cash flow.